You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFencamfamine
Accession NumberDB01463
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionFencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases. [Wikipedia]
Structure
Thumb
Synonyms
Fencamfamin
Fencamfamine
Fencamfaminum
Fencanfamina
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GlucoenerganNot Available
ReactivanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fencamfamine hydrochloride
Thumb
  • InChI Key: CVFSMSTXULJISA-UHFFFAOYNA-N
  • Monoisotopic Mass: 251.144077416
  • Average Mass: 251.795
DBSALT000814
Categories
UNIINME1I5IGBK
CAS number1209-98-9
WeightAverage: 215.3339
Monoisotopic: 215.167399677
Chemical FormulaC15H21N
InChI KeyInChIKey=IKFBPFGUINLYQI-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
IUPAC Name
N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
SMILES
CCNC1C2CCC(C2)C1C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassMonoterpenoids
Direct ParentBicyclic monoterpenoids
Alternative Parents
Substituents
  • Bicyclic monoterpenoid
  • Aromatic monoterpenoid
  • Aralkylamine
  • Cyclohexylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.
PharmacodynamicsFencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.
Mechanism of actionFencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses. This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse. It also stimulates the release of dopamine and norepinephrine into the synapse. Finally, it increases the magnitude of dopamine release after a stimulus, increasing the salience of stimulus. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer. Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOverdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9756
Caco-2 permeable+0.6244
P-glycoprotein substrateNon-substrate0.648
P-glycoprotein inhibitor IInhibitor0.5239
P-glycoprotein inhibitor IIInhibitor0.6499
Renal organic cation transporterNon-inhibitor0.5876
CYP450 2C9 substrateNon-substrate0.7441
CYP450 2D6 substrateNon-substrate0.6052
CYP450 3A4 substrateNon-substrate0.6348
CYP450 1A2 substrateInhibitor0.871
CYP450 2C9 inhibitorNon-inhibitor0.6742
CYP450 2D6 inhibitorInhibitor0.7272
CYP450 2C19 inhibitorInhibitor0.645
CYP450 3A4 inhibitorNon-inhibitor0.7812
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8237
Ames testNon AMES toxic0.7967
CarcinogenicityNon-carcinogens0.7716
BiodegradationNot ready biodegradable0.6553
Rat acute toxicity3.3827 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7712
hERG inhibition (predictor II)Inhibitor0.5827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.20SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00295 mg/mLALOGPS
logP3.46ALOGPS
logP3.21ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)10.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.64 m3·mol-1ChemAxon
Polarizability26.13 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3. [PubMed:1970543 ]
  2. Link [Link]
External Links
ATC CodesN06BA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineFencamfamine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineFencamfamine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fencamfamine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fencamfamine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fencamfamine.
AmisulprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fencamfamine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fencamfamine.
AmoxapineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amperozide.
AmphetamineFencamfamine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.
ArticaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Azaperone.
AzelastineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fencamfamine.
BaclofenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fencamfamine.
BenzphetamineFencamfamine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
BrimonidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fencamfamine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fencamfamine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fencamfamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fencamfamine.
ButacaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fencamfamine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fencamfamine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fencamfamine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fencamfamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fencamfamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fencamfamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fencamfamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorphenamine.
ChlorphentermineFencamfamine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fencamfamine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fencamfamine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fencamfamine.
CitalopramThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fencamfamine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fencamfamine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fencamfamine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fencamfamine.
CyclizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.
CyproheptadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.
DapoxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fencamfamine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fencamfamine.
DesloratadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fencamfamine.
DetomidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fencamfamine.
DextroamphetamineFencamfamine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fencamfamine.
DextromoramideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fencamfamine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fencamfamine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fencamfamine.
DifenoxinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fencamfamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fencamfamine.
DihydromorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fencamfamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fencamfamine.
DoramectinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fencamfamine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
DoxylamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Fencamfamine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fencamfamine.
DrotebanolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fencamfamine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.
EcgonineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fencamfamine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fencamfamine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fencamfamine.
EntacaponeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fencamfamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fencamfamine.
EscitalopramThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fencamfamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fencamfamine.
EthanolFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fencamfamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine.
EthosuximideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.
EtoperidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Felbamate.
FenfluramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fencamfamine.
FexofenadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fencamfamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fencamfamine.
FluspirileneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fencamfamine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fencamfamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fencamfamine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fencamfamine.
GuanfacineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fencamfamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fencamfamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fencamfamine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fencamfamine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fencamfamine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fencamfamine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine.
Hydroxyamphetamine hydrobromideFencamfamine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fencamfamine.
IndalpineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fencamfamine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fencamfamine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fencamfamine.
KetazolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fencamfamine.
LevocabastineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fencamfamine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fencamfamine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fencamfamine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fencamfamine.
LisdexamfetamineFencamfamine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Fencamfamine.
LithiumThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fencamfamine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fencamfamine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fencamfamine.
Lu AA21004The risk or severity of adverse effects can be increased when Fencamfamine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fencamfamine.
MeclizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fencamfamine.
MelperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Melperone.
MephentermineFencamfamine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fencamfamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.
MequitazineFencamfamine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fencamfamine.
MetaxaloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fencamfamine.
MethamphetamineFencamfamine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fencamfamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fencamfamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fencamfamine.
MethsuximideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fencamfamine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fencamfamine.
MetyrosineFencamfamine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fencamfamine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.
MilnacipranThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
MirtazapineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fencamfamine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fencamfamine.
MolindoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fencamfamine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.
NabiloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fencamfamine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fencamfamine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fencamfamine.
NitrazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fencamfamine.
OlanzapineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fencamfamine.
OpiumThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Opium.
OrphenadrineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fencamfamine.
OsanetantThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fencamfamine.
OxprenololThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fencamfamine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fencamfamine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fencamfamine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fencamfamine.
ParaldehydeFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fencamfamine.
ParoxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fencamfamine.
PerampanelThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fencamfamine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fencamfamine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fencamfamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fencamfamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenoxyethanol.
PhentermineFencamfamine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fencamfamine.
PipamperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pomalidomide.
PramipexoleFencamfamine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fencamfamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fencamfamine.
PrimidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fencamfamine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fencamfamine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fencamfamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fencamfamine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fencamfamine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fencamfamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fencamfamine.
PSD502The risk or severity of adverse effects can be increased when Fencamfamine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fencamfamine.
RamelteonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fencamfamine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fencamfamine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fencamfamine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fencamfamine.
RomifidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Romifidine.
RopiniroleFencamfamine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine.
RotigotineFencamfamine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fencamfamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fencamfamine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fencamfamine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fencamfamine.
SertindoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fencamfamine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.
SulpirideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fencamfamine.
SuvorexantThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fencamfamine.
TasimelteonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fencamfamine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fencamfamine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fencamfamine.
TetracaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrodotoxin.
ThalidomideFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fencamfamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fencamfamine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fencamfamine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fencamfamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fencamfamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.
TrazodoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fencamfamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fencamfamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fencamfamine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fencamfamine.
TriprolidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fencamfamine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fencamfamine.
VigabatrinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fencamfamine.
ZiconotideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine.
ZolazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fencamfamine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fencamfamine.
ZonisamideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fencamfamine.
ZotepineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Seyfried CA: Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31. [PubMed:6136281 ]
  2. Li SM, Campbell BL, Katz JL: Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J Pharmacol Exp Ther. 2006 Jun;317(3):1088-96. Epub 2006 Feb 14. [PubMed:16478825 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23